Zika vaccine race spurred by crisis and profit potential : pharmacist

as mentioned in pharmacist

Zika vaccine race spurred by crisis and profit potential

Zika vaccine race spurred by crisis and profit potential

Development of a vaccine for Zika virus has taken on new priority, as the promise of a big financial payoff draws more drug makers into the fray.Demand would likely be heavy, given the potential for the infection to cause severe birth defects and its possible transmission through intimate contact.Business and luxury travelers from wealthy nations probably would represent the most lucrative market for immunization.


coupled with livemint

Bharat Biotech's Zika vaccine ready to enter phase-1 trial

Bharat Biotech's Zika vaccine ready to enter phase-1 trial

Bharat Biotech;s Zika vaccine candidate, which is called Zikavac, is an inactivated vaccine, or the one that contains a dead virus.Hyderabad: Vaccine maker Bharat Biotech International Ltd., which is working on a vaccine candidate to prevent the Zika virus infection in humans, said it had crossed an important milestone by completing pre-clinical studies and has sought government approval to begin phase-1 trials, a top executive said."We have completed pre-clinical toxicology studies in animals successfully, and have sought permission from Drug Controller General of India (DCGI)," said D.V.J.A.


in addition eurekalert

IDRI receives NIH grant to develop RNA-based Zika virus vaccine

IDRI receives NIH grant to develop RNA-based Zika virus vaccine

As Zika cases continue to rise around the world -- and in the United States -- with associated increases in Guillain-Barre syndrome and congenital birth defects, the need for a safe and effective vaccine to protect against Zika virus is greater than ever.IDRI (Infectious Disease Research Institute) has been awarded a $491,000, two-year grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to rapidly develop a novel, safe and effective Zika vaccine by designing and formulating new RNA-based vaccine candidates.As part of the grant, IDRI scientists, led by Dan Stinchcomb, Ph.D., Sr. Vice President for Vaccine Development Viral Disease Programs, and Neal van Hoeven, Ph.D., Senior Scientist, will leverage the Zika virus' own machinery for expression of immunogenic proteins.